In the United Kingdom, migraine attacks concern around 10 million people aged 15-69, whilst the total NHS costs of treating this illness is estimated to be £150 million per year, and the wider economic costs are even higher (NHS, 2020). To reduce the number of migraine attacks amongst people and to decrease the NHS costs, it is crucial to find proper medicine.
Migraine is a moderate to severe type of headache, that usually appears on one side of the head. The pain tends to be throbbing, pulsating, or debilitating. The migraine can attack occasionally or regularly. Scientists have not yet found the exact cause of migraine. However, there are activities and behaviours’ that trigger it. Those are; stress, depression, poor-quality sleep or diet, low blood sugar, smoking, or medicines. Regular migraines have a negative impact on one’s life and can disturb daily activities. (NHS, 2019)
The aim is to introduce the analysis and reveal the results of the two drugs’ effectiveness in treating migraine pain. Migone & Naproxen were tested against a placebo to assess differences between active substances. Finding effective medicine is necessary to help individuals impacted. Economical factors such as lowering the cost of treating migraine are also crucial from a wide social perspective according to (NHS, 2020).
The study took into consideration the efficiency of two drugs (Migone, Naproxen) versus inert substance placebo. The group of 30 participants of both sexes was randomly selected. The age range is from 20 to 60 years old. Doubled tiled T-Test was selected as the appropriate tool to assess the significance of findings. Provided data before and after treatment were used to distinguish efficiency by comparison of intensity and frequency of migraines. Clinical trials lasted three months period. The study compare obtained results. The intensity of migraines is numbered from being mild to extremely debilitating. (0-10)
Graph 1 – The comparison of an average number of migraines before and after trial
As can be seen on Graphs 1, both Migone and Naproxen show the significant ability to decrease the number of migraines and lower their intensity. Placebo shows the irrelevant impact on study groups. Migone shows the acutest difference before and after the trial in the number of migraines (decreased by 50% after trial). Naproxen also appears to be an effective drug in treating migraine (decreased the number of migraines by 35%).
Graph 2 – The comparison of an average intensity after medicine intake.
The study reveals that two drugs Migone & Naproxen are effective in treating migraine pain compared to placebo. Based on results Migone is the most effective drug to treat migraine under trial conditions. Naproxen indicates effectiveness in decreasing the frequency of migraine attack and their intensity. Placebo does not reveal any significant impact on improvement migraine pain. The fact that migraine can attack frequently or can be irregular it’s a study raw data limitation therefore, the results may be not accurate. Moreover, raw data do not include dosages of given substances. Additional data such as individual habits and behavioral protocols introduced during clinical trial will be useful for further research. Raucci, et al. (2021) claim that lifestyle and patient choices may have a significant impact on migraines perceived by patients. Individual live choices may significantly interfere in increasing or decreasing migraine pain. Further research exploring the case should be conducted.
- NHS (2019) ‘Migraine’. Available at: https://www.nhs.uk/conditions/migraine/ (Accessed: 10/03/2022)
- NHS (2020) ‘Improved NHS migraine care to save thousands of hospital stays’. Available at: https://www.england.nhs.uk/2020/01/improved-nhs-migraine-care/#:~:text=In%20total%2C%20it%20is%20estimated,million%20migraine%2Drelated%20sick%20days (Accessed: 10/03/2022)
- Raucci, et al. (2021). ’Lifestyle Modifications to Help Prevent Headache at a Developmental Age. Frontiers in Neurology’ [online] 11, p.618375. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7884344/ [Accessed 18.03.2022].